Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.94)
# 147
Out of 4,556 analysts
223
Total ratings
69.1%
Success rate
42.6%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics | Initiated Coverage: Buy | $39 | $14.85 | +162.63% | 1 | Jul 22, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $91 | $36.30 | +150.69% | 8 | Jul 9, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $88 → $85 | $83.89 | +1.32% | 6 | Jul 8, 2026 | |
| CMPS COMPASS Pathways | Upgraded: Buy | $8 → $21 | $12.15 | +72.84% | 5 | Jul 8, 2026 | |
| JSPR Jasper Therapeutics | Rated: Hold | n/a | $0.7503 | - | 8 | Jul 6, 2026 | |
| RLYB Rallybio | Rated: Hold | n/a | $16.52 | - | 7 | Jul 6, 2026 | |
| DYN Dyne Therapeutics | Maintained: Buy | $33 | $22.13 | +49.12% | 6 | Jun 4, 2026 | |
| AVLN Avalyn Pharma | Initiated Coverage: Buy | $51 | $29.84 | +70.91% | 1 | May 26, 2026 | |
| ABBV AbbVie | Rated: Buy | $236 → $235 | $256.42 | -8.35% | 17 | May 15, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $20 → $19 | $16.18 | +17.43% | 27 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $26 | $18.83 | +38.11% | 11 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $324 → $329 | $253.00 | +30.04% | 13 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $1,007 → $1,059 | $865.61 | +22.34% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 → $33 | $27.98 | +17.94% | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $88 → $120 | $104.59 | +14.73% | 9 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $138 | $115.49 | +19.49% | 19 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $55.99 | -7.13% | 7 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $295 → $300 | $338.94 | -11.49% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 | $49.28 | +31.90% | 3 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $12.25 | +46.94% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $30.23 | +52.17% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $26 | $44.19 | -41.16% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $208 | $107.91 | +92.75% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $9.56 | +77.92% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $55 | $11.86 | +363.74% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.86 | +168.82% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $3.36 | +49.03% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $1.32 | +203.03% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.73 | +46.52% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $5.06 | n/a | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.73 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $117.36 | n/a | 1 | Aug 3, 2022 |
Tenax Therapeutics
Jul 22, 2026
Initiated Coverage: Buy
Price Target: $39
Current: $14.85
Upside: +162.63%
Vera Therapeutics
Jul 9, 2026
Maintained: Buy
Price Target: $91
Current: $36.30
Upside: +150.69%
Crinetics Pharmaceuticals
Jul 8, 2026
Downgraded: Hold
Price Target: $88 → $85
Current: $83.89
Upside: +1.32%
COMPASS Pathways
Jul 8, 2026
Upgraded: Buy
Price Target: $8 → $21
Current: $12.15
Upside: +72.84%
Jasper Therapeutics
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $0.7503
Upside: -
Rallybio
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $16.52
Upside: -
Dyne Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $33
Current: $22.13
Upside: +49.12%
Avalyn Pharma
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $29.84
Upside: +70.91%
AbbVie
May 15, 2026
Rated: Buy
Price Target: $236 → $235
Current: $256.42
Upside: -8.35%
Sarepta Therapeutics
May 15, 2026
Maintained: Hold
Price Target: $20 → $19
Current: $16.18
Upside: +17.43%
May 15, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $18.83
Upside: +38.11%
May 15, 2026
Rated: Buy
Price Target: $324 → $329
Current: $253.00
Upside: +30.04%
May 15, 2026
Rated: Buy
Price Target: $1,007 → $1,059
Current: $865.61
Upside: +22.34%
May 11, 2026
Maintained: Buy
Price Target: $34 → $33
Current: $27.98
Upside: +17.94%
May 11, 2026
Maintained: Buy
Price Target: $88 → $120
Current: $104.59
Upside: +14.73%
May 7, 2026
Maintained: Buy
Price Target: $126 → $138
Current: $115.49
Upside: +19.49%
May 5, 2026
Maintained: Buy
Price Target: $52
Current: $55.99
Upside: -7.13%
May 5, 2026
Maintained: Buy
Price Target: $295 → $300
Current: $338.94
Upside: -11.49%
May 4, 2026
Maintained: Buy
Price Target: $65
Current: $49.28
Upside: +31.90%
Apr 1, 2026
Maintained: Buy
Price Target: $20 → $18
Current: $12.25
Upside: +46.94%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $30.23
Upside: +52.17%
Mar 2, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $44.19
Upside: -41.16%
Feb 26, 2026
Maintained: Buy
Price Target: $208
Current: $107.91
Upside: +92.75%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $9.56
Upside: +77.92%
Feb 10, 2026
Maintained: Buy
Price Target: $40 → $55
Current: $11.86
Upside: +363.74%
Dec 17, 2025
Maintained: Buy
Price Target: $5
Current: $1.86
Upside: +168.82%
Dec 17, 2025
Maintained: Hold
Price Target: $5
Current: $3.36
Upside: +49.03%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $1.32
Upside: +203.03%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $2.73
Upside: +46.52%
Dec 20, 2024
Reiterated: Buy
Price Target: $20 → $18
Current: $5.06
Upside: n/a
May 30, 2023
Maintained: Buy
Price Target: $10
Current: $3.73
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $117.36
Upside: n/a